Worldwide Clinical Trials and Medidata have announced an expanded strategic partnership aimed at transforming clinical research through advanced artificial intelligence and integrated digital solutions. The move is designed to create a more connected, insight-driven model for executing clinical trials with improved efficiency and precision.

As part of the collaboration, Worldwide Clinical Trials becomes the first global contract research organisation to adopt Medidata Plus, gaining enterprise-level access to the full artificial intelligence capabilities of the Medidata platform. This includes the deployment of Dot, Medidata’s AI-powered virtual companion, across study, data and patient experience workflows.

The integration enables end-to-end connectivity across the clinical trial lifecycle, from protocol design and data collection to study close-out. By leveraging a unified AI ecosystem, the partnership aims to enhance data integrity, streamline operations and enable faster, more confident decision-making for trial sponsors and research teams.

Company executives said the adoption of AI at scale will allow for improved transparency, reduced operational complexity and the ability to manage increasingly complex clinical programmes more effectively. The technology is also expected to accelerate timelines and improve overall trial quality, supporting faster delivery of new therapies to patients.

The partnership builds on Medidata’s long-standing role in digital clinical trial solutions, backed by experience across thousands of trials and millions of patients globally. It also aligns with the broader capabilities of parent company Dassault Systèmes, known for its AI-powered virtual twin technologies and innovation platforms.

Worldwide Clinical Trials, which operates in more than 70 countries, provides clinical development services across therapeutic areas including neuroscience, oncology and rare diseases. The company’s flexible service model is expected to further benefit from the enhanced AI-driven infrastructure, enabling more tailored and scalable solutions for biopharmaceutical clients.

The expanded partnership reflects a growing industry shift toward AI-enabled clinical research, where integrated data ecosystems and intelligent automation are becoming central to improving trial outcomes and accelerating drug development.